Category Archives: Advocacy

Federal Update: Tax Reform & Impact on the Life Sciences Sector

Congress is currently advancing legislation in both chambers to significantly overhaul the U.S. tax code. Historically, CLSA has focused our tax-related advocacy efforts around: (1) calling for an update and making permanent of the R&D Tax Credit, (2) protecting the Orphan Drug Tax Credit (ODTC), and (3) opposing the creation of and later calling for a repeal of the medical device tax.

NIH Partners with 9 CLSA Member Biopharma Companies to Accelerate Cancer Therapy Innovation

On Oct. 12, the National Institutes of Health (NIH) announced a new partnership with 11 biopharmaceutical companies aimed at accelerating innovation in new cancer immunotherapy therapies. Nine of the 11 companies are CLSA members: AbbVie; Amgen; Boehringer Ingelheim Pharma GmbH & Co. KG; Bristol-Myers Squibb; Celgene Corporation; Genentech, a member of the Roche Group; Gilead Sciences; Janssen Pharmaceutical Companies of Johnson & Johnson; and Pfizer, Inc.